Can Mineralys Therapeutics(NASDAQ:MLYS) Transform Hypertension Treatment With Lorundrostat's Approaching FDA Decision?

Sonal Goyal

05 November 2026 07:54 PM AEDT

Can Mineralys Therapeutics(NASDAQ:MLYS) Transform Hypertension Treatment With Lorundrostat's Approaching FDA Decision?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

• FDA review of lorundrostat NDA continues with a PDUFA target date of December 22, 2026

• 46% of participants on lorundrostat 50 mg achieved the AHA/ACC systolic BP target of less than 130 mmHg at Week 12

• Lorundrostat reduced albuminuria by 52% versus placebo in patients with chronic kidney disease

• Late-breaking Transform-HTN extension data selected for presentation at AHA Scientific Sessions 2026

Mineralys Therapeutics, Inc.(NASDAQ:MLYS), a biopharmaceutical company developing treatments for hypertension and aldosterone-related conditions, announced its third-quarter 2026 financial results and corporate update on November 4, 2026. The Radnor, Pennsylvania-based company is in the final stretch before a pivotal FDA decision on its lead candidate, lorundrostat, with a Prescription Drug User Fee Act target date set for December 22, 2026.

Lorundrostat Clinical Data Updates

New analyses from the pivotal Phase 3 Launch-HTN trial provided additional detail on lorundrostat's efficacy profile. At Week 12, 46% of participants receiving lorundrostat 50 mg achieved the American Heart Association and American College of Cardiology guideline-recommended office systolic blood pressure target of less than 130 mmHg. More than two-thirds of participants in the lorundrostat arm achieved a systolic blood pressure reduction of 10 mmHg or greater. The trial enrolled patients with uncontrolled or treatment-resistant hypertension despite treatment with two to five antihypertensive therapies.

A separate analysis from Launch-HTN demonstrated that lorundrostat achieved similar blood pressure reductions in participants with and without chronic kidney disease, with consistent efficacy across CKD Stages 1 through 3. Additionally, lorundrostat reduced albuminuria by 52% compared with placebo, validating findings from a prior trial in patients with established CKD.

Final results from the Phase 2 Explore-OSA trial, which evaluated lorundrostat in overweight or obese adults with moderate-to-severe obstructive sleep apnea and hypertension, showed that lorundrostat 50 mg taken once daily in the evening reduced morning systolic blood pressure by 11.1 mmHg at Week 4, compared with a 1.0 mmHg reduction with placebo. No measurable change in the apnea-hypopnea index was observed. The safety profile in the trial was favourable, with no serious safety events, including no hyperkalemia.

Commercialisation Preparations

Mineralys reported that its commercialisation preparations for lorundrostat are advancing on schedule ahead of the PDUFA date. CEO Jon Congleton noted that the company has been meeting with physicians, payers, and people living with hypertension, receiving what he described as positive feedback. The unmet need in the market is considerable, with approximately 20 million adults in the United States living with uncontrolled or resistant hypertension despite treatment.

New long-term efficacy and safety data from the ongoing Transform-HTN open-label extension trial have been selected for a late-breaking presentation at the American Heart Association Scientific Sessions 2026, scheduled for November 6 through 9 in Chicago. These data will provide insight into lorundrostat's durability of effect beyond the timeframes evaluated in the registration trials.

Financial Position

The company did not disclose detailed Q3 financial figures in the initial release summary, consistent with its pre-revenue status. As a clinical-stage biopharmaceutical company, Mineralys' financial trajectory is tied to the outcome of the lorundrostat regulatory review and subsequent commercialisation if approved. The company has been investing in building out its commercial infrastructure, including a sales force and market access capabilities, in preparation for a potential launch.

What Lies Ahead

Mineralys Therapeutics approaches a defining period with the December 22 PDUFA date representing the most significant near-term catalyst. The clinical data package supporting lorundrostat has grown through 2026 with new analyses demonstrating efficacy across multiple patient subgroups, including those with comorbid CKD and OSA. The company's ability to execute a timely and effective launch, should approval be granted, will be the next critical test for the organisation and its shareholders.

FAQs

Q: What is lorundrostat and what does it treat?

A: Lorundrostat is an investigational aldosterone synthase inhibitor being developed by Mineralys Therapeutics for the treatment of hypertension in combination with other antihypertensive drugs.

Q: When is the FDA expected to make a decision on lorundrostat?

A: The PDUFA target date for the lorundrostat NDA is December 22, 2026.

Q: What percentage of patients achieved blood pressure targets on lorundrostat?

A: In the Launch-HTN trial, 46% of participants on lorundrostat 50 mg achieved the AHA/ACC guideline systolic blood pressure target of less than 130 mmHg at Week 12.

Q: How many people in the U.S. have uncontrolled hypertension?

A: Approximately 20 million adults in the United States live with uncontrolled or resistant hypertension despite treatment with available therapies.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.